Stephen J.LurieMD, PhD, Contributing EditorIndividualAuthor
To the Editor: We would like to commend Dr
Vijan and colleagues1 for their contribution
to cost-utility analysis of screening for patients with type 2 diabetes mellitus.
We believe that studies of this nature are crucial for policymakers who will
decide the direction of health care.
Critical to any cost-effective analysis, however, are the utility values
used in the decision analysis process. As Vijan et al state, "The variable
that had the largest impact on the effectiveness of screening was the utility
placed on a year of blindness." In the study, they assigned a utility value
of 0.69 to blindness.
Fontanarosa PB, Brown GC, Brown MM, Sharma S. How Often Should Patients With Diabetes Be Screened for Retinopathy?. JAMA. 2000;284(4):437-439. doi:10.1001/jama.284.4.436